Rituximab Ä¡·á·Î È£ÀüµÈ Àç¹ß¼º º£°Ô³Ê À°¾ÆÁ¾Áõ
A Case of Relapsing Granulomatosis with Polyangiitis Treated Successfully with Rituximab
´ëÇÑ·ù¸¶Æ¼½ºÇÐȸÁö 2014³â 21±Ç 5È£ p.257 ~ p.260
ÇÑÁö¿ø(Han Ji-Won) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
°±Í¿µ(Kang Kwi-Young) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹ÝÅÂÇö(Ban Tae-Hyun) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Á¶ÀÍÇö(Jo Ik-Hyun) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹Ú¼ºÈ¯(Park Sung-Hwan) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
Granulomatosis with polyangiitis (GPA) is a rare anti-neutrophil cytoplasmic antibody associated with systemic disease characterized by granulomas and vasculitis affect-ing small and medium vessels. Neurological manifestations in GPA are less frequent than classical manifestations, such as lung and kidney involvement, and cranial nerve palsies are much rarer. Cyclophosphamide and glucocorti-coids have been conventionally administered as an initial induction immunosuppressive therapy for GPA. However, increasing evidence has demonstrated the efficacy and safety of rituximab, an anti-B cell monoclonal antibody, for the treatment of GPA. Herein, we describe a successful treatment of relapsing GPA with cranial nerve involve-ment using rituximab in a 56-year-old male patient who was previously
Å°¿öµå
Granulomatosis with polyangiitis, Cranial nerve, Rituximab
KMID :
0388220140210050257
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)